Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Bafadhel (Oxford, United Kingdom), N. Barnes (Brentford and London, United Kingdom), S. Bourke (North Shields and Newcastle, United Kingdom), C. Compton (Brentford, United Kingdom), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, AL, United States of America), D. Halpin (Exeter, United Kingdom), M. Han (Ann Arbor, MI, United States of America), B. Hartley (Twickenham, United Kingdom), C. Jones (Research Triangle Park, NC, United States of America), P. Lange (Copenhagen and Herlev, Denmark), S. Lettis (Uxbridge, United Kingdom), D. Lipson (Collegeville and Philadelphia, United States of America), D. Lomas (London, United Kingdom), N. Martin (Brentford and Leicester, United Kingdom), F. Martinez (New York, NY, United States of America), R. Van Der Valk (Brentford, United Kingdom), R. Wise (Baltimore, MD, United States of America), D. Singh (Manchester, United Kingdom). Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD?. 260

Member's Comments

No comment yet.

Related content which might interest you: A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial Source: Eur Respir J, 58 (3) 2004522; 10.1183/13993003.04522-2020 Year: 2021 Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids. Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Effect of COPD exacerbations on early lung function decline under maintenance therapy: blood eosinophil count asbiomarker Source: International Congress 2019 – Eosinophils and FeNO in airway diseases Year: 2019 Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Response to omalizumab treatment according to blood eosinophil count: Results of a French real-world study (STELLAIR) Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Peripheral eosinophil count as a biomarker for the management of COPD: not there yet Source: Eur Respir J, 50 (5) 1702165; 10.1183/13993003.02165-2017 Year: 2017 Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019 Year: 2020 Late Breaking Abstract - Blood eosinophil counts and treatment response in COPD: analyses of IMPACT Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Could eosinophil / neutrophil ratio be used to determine treatment in COPD patients? Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018 The blood eosinophil count as a biomarker in COPD Source: International Congress 2015 – Individualised risk reduction strategies for patients with COPD Year: 2015 Low versus high Th2 asthma: variability of blood eosinophil counts in a longitudinal analysis Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017 Blood eosinophil count as a predictor of treatment response in adult patients with chronic cough Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Peripheral blood eosinophil counts in COPD patients and its relationship with prescription of inhaled corticosteroid in real world setting in Japan. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017 Cost-effectiveness of single-inhaler triple therapy for chronic obstructive pulmonary disease treatment by baseline blood eosinophil count: IMPACT trial Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021 Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018 COPD treatment choices based on blood eosinophils: are we there yet? Source: Breathe, 15 (4) 318; 10.1183/20734735.0254-2019 Year: 2019 Clinical significance of blood neutrophil differential count in patients with COPD Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no! Source: Eur Respir J, 51 (5) 1800730; 10.1183/13993003.00730-2018 Year: 2018 Does eosinophil cationic protein (ECP) predict asthma outcome and response to treatment in asthmatic patients? Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012